Heart Failure, Respiratory Failure
Conditions
Keywords
Cardiovascular, Respiratory, Failure, Heart, Lung, Continuous glucose monitoring, Tight glycemic control, Subcutaneous, Insulin, Algorithm
Brief summary
Stress hyperglycemia, a state of abnormal metabolism with supra-normal blood glucose levels, is often seen in critically ill patients. Tight glycemic control (TGC) was originally shown to reduce morbidity and mortality in a landmark randomized clinical trial (RCT) of adult critically ill surgical patients but has since come under intense scrutiny due to conflicting results in recent adult trials. One pediatric RCT has been published to date that demonstrated survival benefit but was complicated by an unacceptably high rate of severe hypoglycemia. The Heart And Lung Failure - Pediatric INsulin Titration (HALF-PINT) trial is a multi-center, randomized clinical treatment trial comparing two ranges of glucose control in hyperglycemic critically ill children with heart and/or lung failure. Both target ranges of glucose control fall within the range of usual care for critically ill children managed in pediatric intensive care units. The purpose of the study is to determine the comparative effectiveness of tight glycemic control to a target range of 80-110 mg/dL (TGC-1, 4.4-6.1 mmol/L) vs. a target range of 150-180 mg/dL (TGC-2, 8.3-10.0 mmol/L) on hospital mortality and intensive care unit (ICU) length of stay (LOS) in hyperglycemic critically ill children with cardiovascular and/or respiratory failure. This will be accomplished using an explicit insulin titration algorithm and continuous glucose monitoring to safely achieve these glucose targets. Both groups will receive identical standardized intravenous glucose at an age-appropriate rate in order to provide basal calories and mitigate hypoglycemia. Insulin infusions will be titrated with an explicit algorithm combined with continuous glucose monitoring using a protocol that has been safely implemented in 490 critically ill infants and children.
Interventions
IV insulin titration to target a blood glucose of 80-110 mg/dL
Sponsors
Study design
Eligibility
Inclusion criteria
* Cardiovascular failure and/or respiratory failure: 1. Cardiovascular Failure: Dopamine or dobutamine \> 5 mcg/kg/min, or any dose of epinephrine, norepinephrine, phenylephrine, milrinone or vasopressin if used to treat hypotension. 2. Respiratory Failure: Acute mechanical ventilation via endotracheal tube or tracheostomy. * Age \>= 2 weeks and corrected gestational age \>= 42 weeks * Age \< 18 years (has not yet had 18th birthday)
Exclusion criteria
* No longer has cardiovascular or respiratory failure (as defined in inclusion criterion 1), or is expected to be extubated in the next 24 hours * Expected to remain in ICU \< 24 hours * Previously randomized in HALF-PINT * Enrolled in a competing clinical trial * Family/team decision to limit/redirect from aggressive ICU technological support * Chronic ventilator dependence prior to ICU admission (non-invasive ventilation and ventilation via tracheostomy overnight or during sleep are acceptable) * Type 1 or 2 diabetes * Cardiac surgery within prior 2 months or during/planned for this hospitalization (extra-corporeal life support or non-cardiac surgery is acceptable) * Diffuse skin disease that does not allow securement of a subcutaneous sensor * Therapeutic plan to remain intubated for \>28 days * Receiving therapeutic cooling with targeted body temperatures \<34 degrees Celsius * Current or planned ketogenic diet * Ward of the state * Pregnancy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| ICU-Free Days | Study day 28 | 28-day hospital mortality-adjusted ICU length of stay. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 28-day Hospital Mortality | 28 days after randomization | We will collect data on 28-day hospital mortality. |
| Accumulation of Multiple Organ Dysfunction Syndrome (MODS) | 28 days after randomization | Accumulation of MODS during the 28 days following randomization will be measured. MODS is defined as the concurrent dysfunction of two or more organ systems (e.g., acute lung injury and renal failure). The clinical relevance of MODS as a surrogate outcome measure is well recognized in the intensive care community, and there is a clear relationship between the number of dysfunctional organ systems and the risk of death in critically ill children. |
| Ventilator-Free Days | 28 days following randomization | Ventilator-free days during the 28 days following randomization encompasses both reduction in the duration of ventilation and improvement in mortality. The end of the subject's duration of ventilation is defined as the date/time of extubation for subjects who are intubated, or the date/time of the discontinuation of mechanical ventilation for subjects with tracheostomy. |
| Developmental Neurobehavioral Outcomes: VABS-II Composite | One year after ICU course | Reliable, reproducible measures of adaptive functioning, behavior and quality of life will be used to determine outcomes at baseline (CBCL, PedsQL) and at one year after ICU discharge (Vineland-II, CBCL, PedsQL). The goal of baseline data collection is to assess pre-ICU health and quality of life. The results of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) are reported. Scores range from 20-160, with higher scores being better. |
| Participants With Device-Related or Non-Device Related Nosocomial Infection | Up to 48 hours after ICU discharge | We will use Centers for Disease Control's (CDC) most recently published definitions for the following nosocomial infections attributable to the ICU stay: total bloodstream infections including Central Venous Line (CVL)-associated bloodstream infections (BSI), respiratory tract infections including ventilator-associated pneumonias, urinary tract infections, and wound infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. |
| Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety) | Participants will be followed for the duration of ICU stay, an expected average of 8 days | Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked. |
| Incidence of Catheter-Associated Bloodstream Infection | Up to 48 hours after ICU discharge | We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: Central Venous Line (CVL)-associated bloodstream infections (BSI) that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days. |
| Incidence of Catheter-Associated Urinary Tract Infection | Up to 48 hours after ICU discharge | We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: urinary tract infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days. |
| Incidence of Ventilator-Associated Pneumonia | Up to 48 hours after ICU discharge | We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: respiratory tract infections including ventilator-associated pneumonias that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days. |
| 90-day Hospital Mortality | 90 days after randomization | In order to enable direct comparisons between data gathered in HALF-PINT and the prior adult NICE-SUGAR trial, we will collect data on 90-day hospital mortality. |
| Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety) | Participants will be followed for the duration of ICU stay, an expected average of 8 days | Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked. |
| Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety) | Participants will be followed for the duration of ICU stay, an expected average of 8 days | Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked. |
| Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety) | Participants will be followed for the duration of ICU stay, an expected average of 8 days | Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked. |
| Participants With Hypokalemia (<2.5 mmol/L) | Participants will be followed for the duration of ICU stay, an expected average of 8 days | Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked. |
| Nursing Workload: SWAT (Subjective Workload Assessment Technique) Instrument | One nursing shift caring for patient on TGC, at anytime during the patient's hospital stay through the tenth nursing shift for the patient. Shift determined randomly by the last digit of the study ID number, 0-9 (0=shift 10, 1=shift 1, 2=shift 2, etc.). | The workload burden placed upon bedside nurses when managing a patient on TGC will be described. Bedside nurses will be randomly selected to complete an anonymous survey describing their perceptions of workload burden associated with managing a patient during one shift. Using the SWAT (Subjective Workload Assessment Technique) instrument, perceived workload of Pediatric Intensive Care Nurses caring for HALF-PINT patients in TGC group 1 and TGC group 2 were assessed. The SWAT has been used to study the effect of workload in the fields of nursing, pharmacy and medicine. It measures the following burdens: cognitive (mental effort or concentration required for complexity of task), time (amount of spare time, interruptions, overlapping tasks) and psychological stress associated with work that impacts performance. The SWAT uses a ranking system to weight perceived workload which results in an overall score ranging from 0-100, where higher scores indicate higher perceived workload. |
| Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) Instrument | One nursing shift caring for patient on TGC, at anytime during the patient's hospital stay through the tenth nursing shift for the patient. Shift determined randomly by the last digit of the study ID number, 0-9 (0=shift 10, 1=shift 1, 2=shift 2, etc.). | The cognitive burden placed upon bedside nurses when managing a patient on TGC will be described. Bedside nurses will be randomly selected to complete an anonymous survey describing their perceptions of workload burden associated with managing a patient on TGC. Using the NASA-TLX instrument, perceived workload of Pediatric Intensive Care Nurses caring for HALF-PINT patients in TGC group 1 and TGC group 2 were assessed. The instrument uses a ranking system to weight perceived workload which results in an overall sore ranging from 0-100, where higher scores indicate higher perceived workload. It obtains overall perception of workload related to stressful tasks and includes 6 dimensions (cognitive demand, physical demand, time pressure, performance, effort, and frustration. |
| Insulin Algorithm Performance: Time to the Target Range | Until study discharge, up to 28 days following randomization | Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. Ideally, the algorithm will minimize time to glucose target range. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high. |
| Insulin Algorithm Performance: Time in the Target Range | Until study discharge, up to 28 days following randomization | Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. Ideally, the algorithm will maximize time spent in the glucose target range. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high. |
| Insulin Algorithm Performance: Time-Weighted Glucose Average | Until study discharge, up to 28 days following randomization | Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high. |
| Incidence of Wound Infection Incidence of Wound Infection | Up to 48 hours after ICU discharge | We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: wound infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This non-device-related infection will be counted per 1,000 ICU days. |
Countries
Australia, Canada, United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Tight Glycemic Control 1 (TGC-1) Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-1 which will seek to maintain the subject's blood sugar between 80-110 mg/dL. Intravenous insulin may be administered per insulin algorithm.
Insulin: IV insulin titration to target a blood glucose of 80-110 mg/dL | 349 |
| Tight Glycemic Control 2 (TGC-2) Approximately half of the subjects randomized into HALF-PINT will be randomized into TGC-2 which will seek to maintain the subject's blood sugar between 150-180 mg/dL. Intravenous insulin may be administered per insulin algorithm.
Insulin: IV insulin titration to target a blood glucose of 150-180 mg/dL | 349 |
| Total | 698 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Randomized; did not receive intevention | 8 | 2 |
| Overall Study | Withdrawn by parent/guardian | 3 | 2 |
Baseline characteristics
| Characteristic | Tight Glycemic Control 1 (TGC-1) | Tight Glycemic Control 2 (TGC-2) | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 349 Participants | 349 Participants | 698 Participants |
| Age, Categorical >=65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Continuous | 5.5 Years | 6.7 Years | 6.2 Years |
| Region of Enrollment Canada | 1 participants | 1 participants | 2 participants |
| Region of Enrollment United States | 348 participants | 348 participants | 696 participants |
| Sex: Female, Male Female | 164 Participants | 169 Participants | 333 Participants |
| Sex: Female, Male Male | 185 Participants | 180 Participants | 365 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 122 / 349 | 112 / 349 |
| serious Total, serious adverse events | 18 / 349 | 7 / 349 |
Outcome results
ICU-Free Days
28-day hospital mortality-adjusted ICU length of stay.
Time frame: Study day 28
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | ICU-Free Days | 20 Days |
| Tight Glycemic Control 2 (TGC-2) | ICU-Free Days | 19.4 Days |
28-day Hospital Mortality
We will collect data on 28-day hospital mortality.
Time frame: 28 days after randomization
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | 28-day Hospital Mortality | 47 Participants |
| Tight Glycemic Control 2 (TGC-2) | 28-day Hospital Mortality | 32 Participants |
90-day Hospital Mortality
In order to enable direct comparisons between data gathered in HALF-PINT and the prior adult NICE-SUGAR trial, we will collect data on 90-day hospital mortality.
Time frame: 90 days after randomization
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | 90-day Hospital Mortality | 52 Participants |
| Tight Glycemic Control 2 (TGC-2) | 90-day Hospital Mortality | 40 Participants |
Accumulation of Multiple Organ Dysfunction Syndrome (MODS)
Accumulation of MODS during the 28 days following randomization will be measured. MODS is defined as the concurrent dysfunction of two or more organ systems (e.g., acute lung injury and renal failure). The clinical relevance of MODS as a surrogate outcome measure is well recognized in the intensive care community, and there is a clear relationship between the number of dysfunctional organ systems and the risk of death in critically ill children.
Time frame: 28 days after randomization
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Accumulation of Multiple Organ Dysfunction Syndrome (MODS) | 326 Participants |
| Tight Glycemic Control 2 (TGC-2) | Accumulation of Multiple Organ Dysfunction Syndrome (MODS) | 324 Participants |
Developmental Neurobehavioral Outcomes: VABS-II Composite
Reliable, reproducible measures of adaptive functioning, behavior and quality of life will be used to determine outcomes at baseline (CBCL, PedsQL) and at one year after ICU discharge (Vineland-II, CBCL, PedsQL). The goal of baseline data collection is to assess pre-ICU health and quality of life. The results of the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) are reported. Scores range from 20-160, with higher scores being better.
Time frame: One year after ICU course
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Developmental Neurobehavioral Outcomes: VABS-II Composite | 79.9 Score on a scale | Standard Deviation 25.5 |
| Tight Glycemic Control 2 (TGC-2) | Developmental Neurobehavioral Outcomes: VABS-II Composite | 79.4 Score on a scale | Standard Deviation 26.9 |
Incidence of Catheter-Associated Bloodstream Infection
We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: Central Venous Line (CVL)-associated bloodstream infections (BSI) that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days.
Time frame: Up to 48 hours after ICU discharge
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Incidence of Catheter-Associated Bloodstream Infection | 1.94 Infections/1000 CVC days |
| Tight Glycemic Control 2 (TGC-2) | Incidence of Catheter-Associated Bloodstream Infection | 0 Infections/1000 CVC days |
Incidence of Catheter-Associated Urinary Tract Infection
We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: urinary tract infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days.
Time frame: Up to 48 hours after ICU discharge
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Incidence of Catheter-Associated Urinary Tract Infection | 2.19 Infections/1000 bladder catheter days |
| Tight Glycemic Control 2 (TGC-2) | Incidence of Catheter-Associated Urinary Tract Infection | 1.79 Infections/1000 bladder catheter days |
Incidence of Ventilator-Associated Pneumonia
We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: respiratory tract infections including ventilator-associated pneumonias that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This device-related infection will be counted per 1,000 device days.
Time frame: Up to 48 hours after ICU discharge
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Incidence of Ventilator-Associated Pneumonia | 0.94 Infections/1000 ventilator days |
| Tight Glycemic Control 2 (TGC-2) | Incidence of Ventilator-Associated Pneumonia | 0 Infections/1000 ventilator days |
Incidence of Wound Infection Incidence of Wound Infection
We will use Centers for Disease Control's (CDC) most recently published definition for the following nosocomial infection attributable to the ICU stay: wound infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit. This non-device-related infection will be counted per 1,000 ICU days.
Time frame: Up to 48 hours after ICU discharge
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Incidence of Wound Infection Incidence of Wound Infection | 0 Infections/1000 ICU days |
| Tight Glycemic Control 2 (TGC-2) | Incidence of Wound Infection Incidence of Wound Infection | 0 Infections/1000 ICU days |
Insulin Algorithm Performance: Time in the Target Range
Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. Ideally, the algorithm will maximize time spent in the glucose target range. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high.
Time frame: Until study discharge, up to 28 days following randomization
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Insulin Algorithm Performance: Time in the Target Range | 57 Percentage of time |
| Tight Glycemic Control 2 (TGC-2) | Insulin Algorithm Performance: Time in the Target Range | 91 Percentage of time |
Insulin Algorithm Performance: Time to the Target Range
Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. Ideally, the algorithm will minimize time to glucose target range. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high.
Time frame: Until study discharge, up to 28 days following randomization
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Insulin Algorithm Performance: Time to the Target Range | 5.5 Hours |
| Tight Glycemic Control 2 (TGC-2) | Insulin Algorithm Performance: Time to the Target Range | 1.5 Hours |
Insulin Algorithm Performance: Time-Weighted Glucose Average
Performance of the algorithm across diverse ages, weights and disease processes will be critical to measure and compare to other published algorithm performance. We will track the overall glycemic profile using time-weighted glucose average because it is uniquely unaffected by the increased frequency of BG determinations that occur when glucose is abnormally low or high.
Time frame: Until study discharge, up to 28 days following randomization
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Insulin Algorithm Performance: Time-Weighted Glucose Average | 109 mg/dL |
| Tight Glycemic Control 2 (TGC-2) | Insulin Algorithm Performance: Time-Weighted Glucose Average | 123 mg/dL |
Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) Instrument
The cognitive burden placed upon bedside nurses when managing a patient on TGC will be described. Bedside nurses will be randomly selected to complete an anonymous survey describing their perceptions of workload burden associated with managing a patient on TGC. Using the NASA-TLX instrument, perceived workload of Pediatric Intensive Care Nurses caring for HALF-PINT patients in TGC group 1 and TGC group 2 were assessed. The instrument uses a ranking system to weight perceived workload which results in an overall sore ranging from 0-100, where higher scores indicate higher perceived workload. It obtains overall perception of workload related to stressful tasks and includes 6 dimensions (cognitive demand, physical demand, time pressure, performance, effort, and frustration.
Time frame: One nursing shift caring for patient on TGC, at anytime during the patient's hospital stay through the tenth nursing shift for the patient. Shift determined randomly by the last digit of the study ID number, 0-9 (0=shift 10, 1=shift 1, 2=shift 2, etc.).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) Instrument | 35.0 score on a scale |
| Tight Glycemic Control 2 (TGC-2) | Nursing Workload: NASA-TLX (National Aeronautics and Space Administration - Task Load Index) Instrument | 20.4 score on a scale |
Nursing Workload: SWAT (Subjective Workload Assessment Technique) Instrument
The workload burden placed upon bedside nurses when managing a patient on TGC will be described. Bedside nurses will be randomly selected to complete an anonymous survey describing their perceptions of workload burden associated with managing a patient during one shift. Using the SWAT (Subjective Workload Assessment Technique) instrument, perceived workload of Pediatric Intensive Care Nurses caring for HALF-PINT patients in TGC group 1 and TGC group 2 were assessed. The SWAT has been used to study the effect of workload in the fields of nursing, pharmacy and medicine. It measures the following burdens: cognitive (mental effort or concentration required for complexity of task), time (amount of spare time, interruptions, overlapping tasks) and psychological stress associated with work that impacts performance. The SWAT uses a ranking system to weight perceived workload which results in an overall score ranging from 0-100, where higher scores indicate higher perceived workload.
Time frame: One nursing shift caring for patient on TGC, at anytime during the patient's hospital stay through the tenth nursing shift for the patient. Shift determined randomly by the last digit of the study ID number, 0-9 (0=shift 10, 1=shift 1, 2=shift 2, etc.).
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Nursing Workload: SWAT (Subjective Workload Assessment Technique) Instrument | 50.0 score on a scale |
| Tight Glycemic Control 2 (TGC-2) | Nursing Workload: SWAT (Subjective Workload Assessment Technique) Instrument | 36.2 score on a scale |
Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)
Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.
Time frame: Participants will be followed for the duration of ICU stay, an expected average of 8 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety) | 64 Participants |
| Tight Glycemic Control 2 (TGC-2) | Participants With Any Hypoglycemia (<60 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety) | 5 Participants |
Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)
Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.
Time frame: Participants will be followed for the duration of ICU stay, an expected average of 8 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety) | 26 Participants |
| Tight Glycemic Control 2 (TGC-2) | Participants With Any Hypoglycemia (<60 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety) | 29 Participants |
Participants With Device-Related or Non-Device Related Nosocomial Infection
We will use Centers for Disease Control's (CDC) most recently published definitions for the following nosocomial infections attributable to the ICU stay: total bloodstream infections including Central Venous Line (CVL)-associated bloodstream infections (BSI), respiratory tract infections including ventilator-associated pneumonias, urinary tract infections, and wound infections that occur in the ICU or within 48 hours of discharge to the non-ICU inpatient unit.
Time frame: Up to 48 hours after ICU discharge
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Participants With Device-Related or Non-Device Related Nosocomial Infection | 12 Participants |
| Tight Glycemic Control 2 (TGC-2) | Participants With Device-Related or Non-Device Related Nosocomial Infection | 4 Participants |
Participants With Hypokalemia (<2.5 mmol/L)
Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.
Time frame: Participants will be followed for the duration of ICU stay, an expected average of 8 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Participants With Hypokalemia (<2.5 mmol/L) | 76 Participants |
| Tight Glycemic Control 2 (TGC-2) | Participants With Hypokalemia (<2.5 mmol/L) | 64 Participants |
Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety)
Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.
Time frame: Participants will be followed for the duration of ICU stay, an expected average of 8 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety) | 13 Participants |
| Tight Glycemic Control 2 (TGC-2) | Participants With Severe Hypoglycemia (<40 mg/dL), Related to Insulin Infusion (Insulin Algorithm Safety) | 1 Participants |
Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety)
Hypoglycemia will be tracked and reported according to three ranges: severe (\<40 mg/dL), moderate (40-49 mg/dL) and mild (50-59 mg/dL). As insulin infusion can cause slight changes to serum potassium concentration, hypokalemia \<2.5 mmol/L will also be tracked.
Time frame: Participants will be followed for the duration of ICU stay, an expected average of 8 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety) | 5 Participants |
| Tight Glycemic Control 2 (TGC-2) | Participants With Severe Hypoglycemia (<40 mg/dL), Unrelated to Insulin Infusion (Insulin Algorithm Safety) | 6 Participants |
Ventilator-Free Days
Ventilator-free days during the 28 days following randomization encompasses both reduction in the duration of ventilation and improvement in mortality. The end of the subject's duration of ventilation is defined as the date/time of extubation for subjects who are intubated, or the date/time of the discontinuation of mechanical ventilation for subjects with tracheostomy.
Time frame: 28 days following randomization
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Tight Glycemic Control 1 (TGC-1) | Ventilator-Free Days | 21.8 Days |
| Tight Glycemic Control 2 (TGC-2) | Ventilator-Free Days | 20.9 Days |